Affectis Pharmaceuticals Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 2

Employees

  • Latest Deal Type
  • M&A

Affectis Pharmaceuticals General Information

Description

Developer of drugs for the treatment of psychiatric and inflammatory disorders. The company discovers and develops drugs based on findings in the fields of depression, schizophrenia and inflammation.

Contact Information

Formerly Known As
NeuroNova AG
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
LDC Beteiligungen
Vertical(s)
Corporate Office
  • Otto-Hahn-Straße 15
  • 44227 Dortmund
  • Germany

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Affectis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Merger/Acquisition 07-Jan-2014 Completed Generating Revenue
7. Later Stage VC (Series D) 22-Mar-2010 Completed Generating Revenue
6. Grant 08-Jul-2009 Completed Generating Revenue
5. Later Stage VC (Series C) 24-Oct-2006 Completed Startup
4. Grant 18-Oct-2005 Completed Startup
3. Early Stage VC (Series B) 13-Apr-2005 Completed Startup
2. Grant 31-Jan-2005 $982K $4.65M Completed Startup
1. Early Stage VC (Series A) 10-Nov-2003 $4.65M $4.65M Completed Startup
To view Affectis Pharmaceuticals’s complete valuation and funding history, request access »

Affectis Pharmaceuticals Patents

Affectis Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2012163456-A1 Novel p2x7r antagonists and their use Inactive 27-May-2011
WO-2012163792-A1 Novel p2x7r antagonists and their use Inactive 27-May-2011
WO-2012110190-A1 Novel p2x7r antagonists and their use Inactive 17-Feb-2011
AU-2011252351-A1 Novel methods for the preparation of p2x7r antagonists Inactive 14-May-2010
CA-2799115-A1 Novel methods for the preparation of p2x7r antagonists Inactive 14-May-2010 C07D209/40
To view Affectis Pharmaceuticals’s complete patent history, request access »

Affectis Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Affectis Pharmaceuticals Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Adamant Biomedical Investment Asset Manager Minority
Aescap Life Sciences Mutual Fund Minority
Bayern Kapital Venture Capital Minority
EMBL Ventures Venture Capital Minority
EQT Life Sciences Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Affectis Pharmaceuticals FAQs

  • When was Affectis Pharmaceuticals founded?

    Affectis Pharmaceuticals was founded in 2002.

  • Where is Affectis Pharmaceuticals headquartered?

    Affectis Pharmaceuticals is headquartered in Dortmund, Germany.

  • What is the size of Affectis Pharmaceuticals?

    Affectis Pharmaceuticals has 2 total employees.

  • What industry is Affectis Pharmaceuticals in?

    Affectis Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Affectis Pharmaceuticals a private or public company?

    Affectis Pharmaceuticals is a Private company.

  • What is Affectis Pharmaceuticals’s current revenue?

    The current revenue for Affectis Pharmaceuticals is .

  • How much funding has Affectis Pharmaceuticals raised over time?

    Affectis Pharmaceuticals has raised $29.5M.

  • Who are Affectis Pharmaceuticals’s investors?

    Adamant Biomedical Investment, Aescap Life Sciences, Bayern Kapital, EMBL Ventures, and EQT Life Sciences are 5 of 7 investors who have invested in Affectis Pharmaceuticals.

  • When was Affectis Pharmaceuticals acquired?

    Affectis Pharmaceuticals was acquired on 07-Jan-2014.

  • Who acquired Affectis Pharmaceuticals?

    Affectis Pharmaceuticals was acquired by LDC Beteiligungen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process